For the Inventor, By the Inventor

Enter assignee name

Berlin, Germany

Bayer Pharma Aktiengesellschaft

Calculating rank

USPTO Granted Patents = 387

% Expired Patents = 42.4

CIPO Patents = 20

EPO Patents = 266

Trademarks = 15

Forward Citations = 1,259

Loading Chart...

Loading Chart...

853 inventors (with patents filed for the assignee):

Philip Lienau (52 out of 80 patents)

Gerhard Siemeister (38 out of 78 patents)

Frank Wunder (36 out of 98 patents)

4. Ulf Bömer (33 out of 70 patents)

5. Johannes-Peter Stasch (31 out of 150 patents)

6. Adrian Tersteegen (30 out of 53 patents)

7. Hanna Tinel (29 out of 32 patents)

8. Knut Eis (27 out of 41 patents)

9. Karl-Heinz Schlemmer (26 out of 120 patents)

10. Alexandros Vakalopoulos (26 out of 52 patents)

11. Johannes Platzek (25 out of 129 patents)

12. Martina Schäfer (25 out of 30 patents)

13. Ulrich Klar (23 out of 77 patents)

14. Ulrich Lücking (23 out of 38 patents)

15. Antje Margret Wengner (23 out of 29 patents)

Core Competencies:

Indazoles

Gadolinium Chelates

Cancer Treatment

Guanylate Cyclase

Antibody Drug Conjugates

PDE Inhibitors

Autoimmune Diseases

Cardiopulmonary Disorders

Triazolones

Prodrugs

MKNK Inhibitors

AHR Inhibitors

387 patents: Sort by Forward Citations

1. RE51068 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient (2026-10-13),

2. 12559473 - Substituted indazoles, methods for the production thereof, pharmaceutical preparations that contain said new substituted indazoles, and use of said new substituted indazoles to produce drugs (2026-02-24),

3. 12503491 - MASP INHIBITORY COMPOUNDS AND USES THEREOF (2025-12-23),

4. 12486248 - 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH (2025-12-02),

5. 12478696 - Gadolinium chelate compounds for use in magnetic resonance imaging (2025-11-25),

6. 12459916 - Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals (2025-11-04),

7. 12448381 - Method for the preparation of (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide by racemate separation by means of diastereomeric tartaric acid esters (2025-10-21),

8. 12427131 - Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof (2025-09-30),

9. 12358877 - Synthesis of 4-amino-5-methyl-1H-pyridin-2(1H)-on (intermediate compound for the synthesis of the MR antagonist finerenone) from 2-chloro-5-methyl-4-nitro-pyridine-1-oxide using the intermediate compound 2-chloro-5-methyl-4-pyridinamine (2025-07-15),

10. 12303573 - Formulation of contrast media and process of preparation thereof (2025-05-20),

11. 12258343 - Method for preparing 2-[(3R)-3-methylmorpholin-4-yl]-4-[1-methyl-1H-pyrazol-5-yl)-8-(1H-pyrazol-5-yl)-1,7-naphthyridine (2025-03-25),

12. 12258323 - Dihydrooxadiazinones (2025-03-25),

13. 12239630 - Carboxylic acid aromatic amides as antagonists of bradykinin B1 receptor (2025-03-04),

14. 12202805 - Process for preparing (5S)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound (2025-01-21),

15. 12180227 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2024-12-31),

Company Overview

Bayer Pharma Aktiengesellschaft, headquartered in Berlin, Germany, specializes in pharmaceutical chemistry with a focus on innovative treatments for various health conditions. The company is engaged in the development and manufacturing of advanced therapeutic solutions, particularly in the areas of cancer treatment, autoimmune diseases, and cardiopulmonary disorders. Key technological domains include indazoles, gadolinium chelates, guanylate cyclase, antibody drug conjugates, and PDE inhibitors, reflecting its commitment to addressing complex medical challenges.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

387 Patents

#2 in D-1000 Berlin

#148 in Germany

#2,397 in the World

Berlin, Germany

Bayer Pharma Aktiengesellschaft

Forward Citations = 1,259

853 inventors:

Philip Lienau (52 out of 80 patents)

Gerhard Siemeister (38 out of 78 patents)

Frank Wunder (36 out of 98 patents)

4. Ulf Bömer (33 out of 70 patents)

5. Johannes-Peter Stasch (31 out of 150 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bayer Pharma Aktiengesellschaft. Retrieved from https://idiyas.com/company/bayer-pharma-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…